Evaluation of the interaction potential of synthetic ethylene glycol compounds with nuclear Factor B

Authors

  • Srinivasan Narasimhan Asthagiri Herbal Research Foundation, 162A, Perungudi Industrial Estate, Perungudi, Chennai, India 600096
  • Amin F. Majdalawieh Department of Biology, Chemistry and Environmental Sciences, American University of Sharjah, P.O. Box 26666, Sharjah, United Arab Emirates
  • Imad A. Abu-Yousef Department of Biology, Chemistry and Environmental Sciences, American University of Sharjah, P.O. Box 26666, Sharjah, United Arab Emirates
  • Dhivya Shanmugarajan Asthagiri Herbal Research Foundation, 162A, Perungudi Industrial Estate, Perungudi, Chennai, India 600096
  • Vishvanathan Ramasubramanian Asthagiri Herbal Research Foundation, 162A, Perungudi Industrial Estate, Perungudi, Chennai, India 600096

DOI:

https://doi.org/10.13171/mjc.2.3.2013.02.01.11

Abstract

 In the last three decades, nuclear factor ï«B (NF-ï«B) has been the focus of many researchers who are interested in understanding the various molecular mechanisms involved in inflammatory diseases and cancer. Interference with NF-ï«B activity can cause many cellular abnormalities including tumorigenesis. In this study, we focus on examining the potential of ten synthetic ethylene glycol based compounds to interact with the binding site of NF-ï«B. Computational analysis reveals that the ethylene glycol compounds examined in this study display differential ability to interact with NF-ï«B. Parameters such as ALOGP, dock score, and internal energy were determined for each of the studied compounds. Seven compounds were found to interact with specific amino acid residues within the binding site of NF-ï«B. The specific amino acids involved in the interaction were mapped and the nature of interaction was identified. Since NF-ï«B is implicated in the development of many inflammatory and immune-related conditions including cancer, we predict that the ethylene glycol compounds examined in this study can be targeted for the development of therapeutic agents that can be employed in the prevention and/or treatment of various diseases including cancer.

References

P. P. Tak, G. S. Firestein, J. Clin. Invest., 2001, 107, 7-11.

Y. Yamamoto, R. B. Gaynor, J. Clin. Invest., 2001, 107, 135-142.

S. E. Shoelson, J. Lee, M. Yuan, Int. J. Obes. Relat. Metab. Disord., 2003, 27, S49-S52.

H. Clevers, Cell, 2004, 118, 671-674.

A. Kumar, Y. Takada, A. M. Boriek, B. B. Aggarwal, J. Mol. Med., 2004, 82, 434-448.

C. Monaco, E. Paleolog, Cardiovasc. Res., 2004, 61, 671-682.

A. F. Majdalawieh, H. S. Ro, Mediators Inflamm., 2010, 2010, 823821.

W. C. Sha, H. C. Liou, E. I. Tuomanen, D. Baltimore, Cell, 1995, 80, 321-330.

F. Weih, D. Carrasco, S. K. Durham, D. S. Barton, C. A. Rizzo, R. P. Ryseck, S. A. Lira, R. Bravo, Cell, 1995, 80, 331-340.

F. Kontgen, R. J. Grumont, A. Strasser, D. Metcalf, R. Li, D. Tarlinton, S. Gerondakis, Genes Dev., 1995, 9, 1965-1977.

J. H. Caamano, C. A. Rizzo, S. K. Durham, D. S. Barton, C. Raventos-Suarez, C. M. Snapper, R. Bravo, J. Exp. Med., 1998, 187, 185-196.

G. Franzoso, L. Carlson, L. Poljak, E. W. Shores, S. Epstein, A. Leonardi, A. Grinberg, T. Tran, T. Scharton-Kersten, M. Anver, P. Love, K. Brown, U. Siebenlist, J. Exp. Med., 1998, 187, 147-159.

P. A. Baeuerle, D. Baltimore, Genes Dev., 1989, 3, 1689-1698.

S. Ghosh, D. Baltimore, Nature, 1990, 344, 678-682.

M. J. May, S. Ghosh, Semin. Cancer Biol., 1997, 8, 63-73.

A. Israel, Trends Cell Biol., 2000, 10, 129-133.

M. S. Hayden, S. Ghosh, Genes Dev., 2004, 18, 2195-2224.

W. Wang, H. L. McLeod, J. Cassidy, Int. J. Cancer, 2003, 104, 504-511.

Y. Q. Li, Z. X. Zhang, Y. J. Xu, W. Ni, S. X. Chen, Z. Yang, D. Ma, Acta. Pharmacol. Sin., 2006, 27, 339-346.

R. Schreck, B. Meier, D. N. Mannel, W. Droge, P. A. Baeuerle, J. Exp. Med., 1992, 175, 1181-1194.

T. Aoki, H. Kataoka, R. Ishibashi, H. Nakagami, K. Nozaki, R. Morishita, N. Hashimoto, Neurosurgery, 2009, 64, 357-366.

S. Yamagishi, T. Matsui, K. Nakamura, H. Inoue, M. Takeuchi, S. Ueda, K. Fukami, S. Okuda, T. Imaizumi, Microvasc. Res., 2008, 75, 130-134.

J. Patocka, Z. Hon, Acta Medica, 2010, 53, 19-23.

R. Hess, M. J. Bartels, L. H. Pottenger, Arch Toxicol., 2004, 78, 671-680.

K. Gekko, T. Morikawa, J. Biochem., 1981, 90, 51-60.

D. Freifelder, Physical Biochemistry Applications to Biochemistry and Molecular Biology, 2nd ed., W.H. Freeman, New York, 1984.

R. H. Al-Shakhshir, F. E. Regnier, J. L. White, S. L. Hem, Vaccine, 1995, 13, 41-44.

S. L. Yowell, S. Blackwell, Cancer Treatment Rev., 2002, 28, S3-S6.

H. Wada, I. Imamura, M. Sako, S. Katagiri, S. Tarui, H. Nishimura, Y. Inada, Ann. NY Acad. Sci., 1990, 613, 95-108.

G. E. Francis, C. Delgado, D. Fisher, F. Malik, A. K. Agrawal, J. Drug Target., 1996, 3, 321-340.

C. L. van den Berg, G. N. Cox, C. A. Stroh, S. G. Hilsenbeck, C. N. Weng, M. J. McDermott, D. Pratt, C. K. Osborne, E. B. Coronado-Heinsohn, D. Yee, Eur. J. Cancer, 1997, 33, 1108-1113.

S. Narasimhan, S. Gopi, V. Ramasubramanian, D. P. Matharasi, S. Kannan, Indian Patent Application: 1951/CHE/2009.

http://www.uniprot.org

H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, P. E. Bourne, Nucleic Acids Res., 2000, 28, 235-242.

H. M. Berman, Acta Crystallographica Section A: Foundations of Crystallography, 2008, A64, 88-95.

http://accelrys.com/resource-center/downloads/updates/discovery-studio/dstudio25/dstudio 255.html

C. M. Venkatachalam, X. Jiang, T. Oldfield, M. Waldman, J. Mol. Graph. Model, 2003, 21, 289-307.

A. K. Ghose, G. M. Crippen, J. Comput. Chem., 1986, 7, 565-577.

A. K. Ghose, G. M. Crippen, J. Chem. Inf. Comput. Sci., 1987, 27, 21-35.

V. N. Viswanadhan, A. K. Ghose, G. R. Revankar, R. K. Robins, J. Chem. Inf. Comput. Sci., 1989, 29, 163-172.

A. K. Ghose, A. Pritchett, G. M. Crippen, J. Comput. Chem., 1988, 9, 80-90.

A. K. Ghose, V. N. Viswanadhan, J. J. Wendoloski, J. Phys. Chem. A., 1998, 102, 3762-3772.

C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Adv. Drug Del. Rev., 1997, 23, 3-25.

C. A. Lipinski, F. Lombardo, B.W. Dominy, P. J. Feeney, Adv. Drug Del. Rev., 2001, 46, 3-26.

T. I. Oprea, A. M. Davis, S. J. Teague, P. D. Leeson, J. Chem. Inf. Comput. Sci., 2001, 41, 1308-1315.

Downloads

Published

2013-01-02

Issue

Vol. 2 No. 3 (2013)

Section

Organic Chemistry

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).